Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma.
In recent years, more effective and less toxic treatment protocols have been developed to increase the cure rates in intermediate and high grade non-Hodgkin's lymphoma (NHL). This study was undertaken to investigate the efficacy and toxicity of MINE (ifosfamide, mesna, mitoxantrone and etoposide) combination chemotherapy in patients with intermediate and high grade NHL. Twenty-one patients (16 male, 5 female; age between 26 and 70 years) with NHL were included in the study. An overall response rate of 73% and complete response rate of 56% were achieved and survival rate for responding patients was 80% at the 48th month. Side effects including mild myelosuppression, nausea/vomiting and alopecia were observed. MINE combination seems to be effective and well tolerated without significant toxicity as a first-line therapy in patients with intermediate or high grade NHL.
Aydogdu
I
I
Department of Hematology, School of Medicine, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey.
Koc
H
H
Ilhan
O
O
Gurman
G
G
Akan
H
H
Beksac
M
M
Konuk
N
N
Uysal
A
A
Ozerol
E
E
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D015080:Mesna / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
D005047:Etoposide; D008942:Mitoxantrone; D015080:Mesna; D007069:Ifosfamide